Keryx Biopharma (KERX) Misses Q1 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. USO
5. GNK
6. PLUR
7. MU
8. ARGX
9. AZN
10. SPCX

Go back to Keryx Biopharma (KERX) Misses Q1 EPS by 13c

Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results

April 28, 2016 7:02 AM EDT

Company reported $6.8 million in first quarter total revenues, including $5.6 million of Auryxia (ferric citrate) net U.S. product sales2016 product sales and cash operating expense guidance reiteratedCompany on track to submit supplemental new drug application (sNDA) in the third quarter of 2016 seeking to expand ferric citrates indication

BOSTON, April 28, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced its financial results for the first quarter ended... More